Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adimab Enters into Agreement with Acceleron Pharma 11
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 12
Licensing Agreements 13
Acceleron Pharma Enters into Licensing Agreement with Celgene 13
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15
Equity Offering 16
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 20
Acceleron Pharma Completes IPO For US$96.3 Million 22
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 24
Acceleron Pharma Raises USD30 Million in Private Placement of Shares 26
Acceleron Pharma Inc – Key Competitors 27
Acceleron Pharma Inc – Key Employees 28
Acceleron Pharma Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Aug 03, 2017: Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results 30
May 08, 2017: Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results 32
Mar 01, 2017: Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results 34
Nov 03, 2016: Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results 36
Aug 04, 2016: Acceleron Pharma Reports Second Quarter 2016 Financial and Operational Results 38
May 05, 2016: Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results 40
Feb 25, 2016: Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights 42
Corporate Communications 45
Nov 15, 2017: Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire 45
May 02, 2017: Acceleron Announces Management Change 46
Sep 27, 2016: Acceleron Announces Retirement of John Knopf as President and CEO; Habib Dable Named as Successor 47
Jul 25, 2016: Acceleron Pharma Appoints Thomas McCourt to its Board of Directors 48
Product News 49
11/01/2017: Acceleron to Present Sotatercept Clinical Data at 59th American Society of Hematology Annual Meeting and Exposition 49
05/19/2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association 50
Clinical Trials 51
Nov 14, 2017: Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions 51
Nov 01, 2017: Acceleron to Present Clinical Presentations on Investigational Drug Candidate Luspatercept at 59th American Society of Hematology Annual Meeting and Exposition 52
Sep 19, 2017: Acceleron Provides Clinical Update on Luspatercept at 2017 R&D Day 53
Sep 19, 2017: Acceleron Provides Clinical Update on Sotatercept at 2017 R&D Day 54
Sep 19, 2017: Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension 55
Sep 05, 2017: Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology 56
Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 57
Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 59
Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 61
May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 62
May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 63
Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 65
Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 66
Dec 05, 2016: Acceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology 67
Dec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology 68
Dec 04, 2016: Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology 69
Jun 10, 2016: Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Beta-Thalassemia Presented at the 21st Congress of the European Hematology Association 70
Jun 10, 2016: Acceleron and Celgene Announce Updated Results from an Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 21st Congress of the European Hematology Association 72
Other Significant Developments 74
Jan 06, 2017: Acceleron Outlines Corporate Goals and Priorities for 2017 74
Appendix 75
Methodology 75
About GlobalData 75
Contact Us 75
Disclaimer 75
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acceleron Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acceleron Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acceleron Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Adimab Enters into Agreement with Acceleron Pharma 11
Acceleron Pharma Enters Into Co-Development Agreement With Celgene For ACE-536 12
Acceleron Pharma Enters into Licensing Agreement with Celgene 13
Acceleron Pharma Enters into Licensing Agreement with Beth Israel Deaconess Medical Center 15
Acceleron Pharma Raises USD230 Million in Public Offering of Shares 16
Acceleron Pharma Raises USD150 Million in Public Offering of Shares 18
Acceleron Pharma Completes Public Offering Of Shares For US$138 Million 20
Acceleron Pharma Completes IPO For US$96.3 Million 22
Acceleron Pharma Completes Private Placement Of Shares For US$10 Million 24
Acceleron Pharma Raises USD30 Million in Private Placement of Shares 26
Acceleron Pharma Inc, Key Competitors 27
Acceleron Pharma Inc, Key Employees 28